Sociodemographic trends in prostate cancer: Insights from the all of Us research program

Clicks: 55
ID: 319451
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #30 of 78 articles by views in jnci cancer spectrum

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Prostate cancer (PCa) disproportionately affects vulnerable populations. The All of Us Research Program (AoURP) is a database that aims to encapsulate the diversity of the U.S. To explore the utility of this dataset in assessing PCa disparities, we investigated whether treatment usage, disease progression, and genomic research participation vary across sociodemographic factors among AoURP participants with PCa. Methods We identified AoURP participants with PCa. Genomic research participation in AoURP, treatment usage, time-to-treatment (TTT), and time-to-metastasis (TTM) were assessed by demographics and distance from a National Cancer Institute-designated comprehensive cancer center (NCIDCCC). Multivariable logistic regression and Cox proportional hazards regression were performed to evaluate treatment usage and TTT and TTM, respectively. Results We observed lower genomic data availability in Black versus White patients (p < 0.001). In multivariable analyses, patients residing >80 miles from an NCIDCCC were less likely to receive ARPIs (OR = 0.30, 95% CI 0.14–0.66, p=.002) and BTAs (OR = 0.46, 95% CI 0.30–0.70, p<.001) but more likely to undergo prostatectomy (OR = 1.97, 95% CI 1.43–2.71, p<.001) than those <40 miles. These patients also initiated treatment faster (HR = 1.54, 95% CI 1.27–1.87, p<.001) and developed metastasis slower (HR = 0.58, 95% CI 0.40–0.86, p=.006). Black patients were less likely to receive radiation (OR = 0.45, 95% CI 0.23–0.88, p=.020), prostatectomy (OR = 0.65, 95% CI 0.44–0.96, p=.028), and BTAs (OR = 0.65, 95% CI 0.45–0.93, p=.018) than White patients. Conclusions PCa treatment usage, disease progression, and genomic research participation varied between demographic populations. As AoURP matures, additional studies may leverage future data releases to confirm these findings.
Reference Key
openalex_W7167012772 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Dhruv G Pillai, Vivian A. Guedes, N Micheletti, Jessica D. Kindrick, Benjamin C Brim, Hyoyoung Choo-Wosoba, Cindy H Chau, W Douglas Figg
Are you one of these authors? Claim your profile
Journal jnci cancer spectrum
Year 2026
DOI
10.1093/jncics/pkag070
URL
https://doi.org/10.1093/jncics/pkag070
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.